Trial Profile
A phase I study of MicroVAX vaccine in patients with various cancers that have relapsed after initial salvage therapy
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Aug 2014
Price :
$35
*
At a glance
- Drugs CD40 ligand MUC1 loaded dendritic cell vaccine (Primary)
- Indications Cancer
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors National Cancer Centre (Singapore)
- 18 Aug 2014 New trial record